The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
Abstract
CONTEXT: Second cancer is the leading cause of death in long-term survivors of Hodgkin disease (HD), with exceptionally high risks of breast cancer among women treated at a young age. Quantitative associations between radiotherapy dose delivered to the breast and administered chemotherapy have not been reported to date in large series, nor has the influence of ovarian exposures on subsequent risk. OBJECTIVE: To quantify the long-term risk of breast cancer associated with use of radiotherapy and chemotherapy to treat young women with HD. DESIGN, SETTING, AND SUBJECTS: Matched case-control study of breast cancer within a cohort of 3817 female 1-year survivors of HD diagnosed at age 30 years or younger, between January 1, 1965, and December 31, 1994, and within 6 population-based cancer registries. The study was conducted March 1, 1996, through September 30, 1998. MAIN OUTCOME MEASURES: Relative risk (RR) of breast cancer associated with radiation dose delivered to site of breast cancer or to ovaries and with cumulative dose of alkylating agents. RESULTS: Breast cancer occurred in 105 patients with HD who were matched to 266 patients with HD but without breast cancer. A radiation dose of 4 Gy or more delivered to the breast was associated with a 3.2-fold (95% confidence interval [CI], 1.4-8.2) increased risk, compared with the risk in patients who received lower doses and no alkylating agents. Risk increased to 8-fold (95% CI, 2.6-26.4) with a dose of more than 40 Gy (P<.001 for trend). Radiation risk did not vary appreciably by age at exposure or reproductive history. Increased risks persisted for 25 or more years following radiotherapy (RR, 2.3; 95% CI, 0.5-16.5; P =.03 for trend with dose). Treatment with alkylating agents alone resulted in a reduced risk (RR, 0.6; 95% CI, 0.2-2.0) of breast cancer, and combined alkylating agents and radiotherapy in a 1.4-fold (95% CI, 0.6-3.5) increased risk. Risk of breast cancer decreased with increasing number of alkylating agent cycles (P =.003 for trend). Risk also was low (RR, 0.4; 95% CI, 0.1-1.1) among women who received 5 Gy or more delivered to ovaries compared with those who received lower doses. CONCLUSIONS: Hormonal stimulation appears important for the development of radiation-induced breast cancer, as evidenced by the reduced risk associated with ovarian damage from alkylating agents or radiation. The high radiation-related risk, which did not diminish at the highest doses or the longest follow-up, however, suggests the need for lifetime surveillance and programs of patient and public awareness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,988
Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease
DEVITA, V. T., SERPICK, A. A., & CARBONE, P. P. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-73-6-881 · Cited by 1,436
Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD
Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., & Peterson, B. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272102 · Cited by 1,148
Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk
Schairer, C. (2000) · JAMA · doi:10.1001/jama.283.4.485 · Cited by 1,048
Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F., & Meadows, A. T. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341201 · Cited by 905
Huerta, G. T., & Villasana, J. E. M. (1988) · PubMed · Cited by 804
Neglia, J. P., Friedman, D. L., Yasui, Y., Mertens, A. C., Hammond, S., Stovall, M., Donaldson, S. S., Meadows, A. T., & Robison, L. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.618 · Cited by 741
Self-citationDores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., van Leeuwen, F. E., Holowaty, E. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.038 · Cited by 565
Self-citationLung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease
Travis, L. B. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.182 · Cited by 562
Self-citationBreast Cancer After Treatment of Hodgkin's Disease
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.25 · Cited by 536
Radiation Effects on Breast Cancer Risk: A Pooled Analysis of Eight Cohorts
Preston, D. L., Mattsson, A., Holmberg, E., Shore, R., Hildreth, N. G., & Boice, J. D. (2002) · Radiation Research · doi:10.1667/0033-7587(2002)158[0220:reobcr]2.0.co;2 · Cited by 512
Self-citationSwerdlow, A. J., Barber, J. A., Hudson, G. V., Cunningham, D., Gupta, R. K., Hancock, B. W., Horwich, A., Lister, T. A., & Linch, D. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.498 · Cited by 476
van Leeuwen, F. E., Klokman, W. J., Veer, M. B. V., Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.487 · Cited by 436
Self-citationMenopause and Breast Cancer Risk 2
(1972) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/48.3.605 · Cited by 421
van Leeuwen, F. E., Klokman, W. J., Stovall, M., Dahler, E. C., van't Veer, M. B., Noordijk, E. M., Crommelin, M. A., Aleman, B. M. P., Broeks, A., Gospodarowicz, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.971 · Cited by 402
Self-citationStovall, M., Blackwell, C. R., Cundiff, J., Novack, D. H., Palta, J. R., Wagner, L. K., Webster, E. W., & Shalek, R. J. (1995) · Medical Physics · doi:10.1118/1.597525 · Cited by 400
Self-citationHormone Replacement Therapy in Relation to Breast Cancer
Chen, C.-L. (2002) · JAMA · doi:10.1001/jama.287.6.734 · Cited by 360
Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer
Travis, L. B., Holowaty, E. J., Bergfeldt, K., Lynch, C. F., Kohler, B. A., Wiklund, T., Curtis, R. E., Hall, P., Andersson, M., Pukkala, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902043400504 · Cited by 359
Self-citationComparison of pharmacodynamic properties of various estrogen formulations
Mashchak, C. A., Lobo, R. A., Dozono-Takano, R., Eggena, P., Nakamura, R. M., Brenner, P. F., & Mishell, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90218-6 · Cited by 316
Hodgkin's disease: Complications of therapy and excess mortality
Hoppe, R. T. (1997) · Annals of Oncology · doi:10.1093/annonc/8.suppl_1.s115 · Cited by 192
Menstrual factors in relation to breast cancer risk.
Titus-Ernstoff, L. T., Longnecker, M. P., Newcomb, P. A., Dain, B., Greenberg, E. R., Mittendorf, R. L., Stampfer, M. J., & Willett, W. C. (1998) · PubMed · Cited by 162
Management of Breast Cancer After Hodgkin’s Disease
Wolden, S. L., Hancock, S. L., Carlson, R. W., Goffinet, D. R., Jeffrey, S. S., & Hoppe, R. T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.765 · Cited by 158
Problems in Hodgkin’s Disease Management
Aisenberg, A. C. (1999) · Blood · doi:10.1182/blood.v93.3.761 · Cited by 129
Breast cancer risk associated with gynecologic surgery and indications for such surgery
Schairer, C., Persson, I. R., Falkeborn, M., Naessén, T., Troisi, R. J., & Brinton, L. A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970117)70:2<150::aid-ijc2>3.0.co;2-w · Cited by 125
Breast cancer risk following irradiation for Hodgkin’s disease
Clemons, M. J., Loijens, L., & Goss, P. E. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0174 · Cited by 114
Diller, L., Medeiros-Nancarrow, C., Shaffer, K., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.031 · Cited by 110
Tissue doses from radiotherapy of cancer of the uterine cervix
Stovall, M., Smith, S. A., & Rosenstein, M. (1989) · Medical Physics · doi:10.1118/1.596331 · Cited by 93
Self-citationMortality in a cohort of women given X‐ray therapy for metropathia haemorrhagica
Darby, S. C., Reeves, G., Key, T. J., Doll, R., & Stovall, M. A. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560606 · Cited by 76
Self-citationA comparative study of prescribing of hormone replacement therapy in USA and Europe
Jolleys, J. V., & Olesen, F. (1996) · Maturitas · doi:10.1016/0378-5122(95)00952-3 · Cited by 60
Radiation dose and breast cancer risk in patients treated for cancer of the cervix
Boice, J. D., Blettner, M., Kleinerman, R. A., Engholm, G., Stovall, M., Lisco, H., Austin, D. F., Bosch, A., Harlan, L. C., Krementz, E. T., et al. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910440103 · Cited by 58
Self-citationStaratschek‐Jox, A., Wolf, J., & Diehl, V. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46877-8_11 · Cited by 58
Hodgkin's Lymphoma: Basing the Treatment on the Evidence
Connors, J. M., Noordijk, E. M., & Horning, S. J. (2001) · Hematology · doi:10.1182/asheducation-2001.1.178 · Cited by 37
Cohen, M., Jones, D. E. A., & Greene, D. (1983) · PubMed · Cited by 32
Synergism between radiation and other risk factors for breast cancer
Shore, R. E., Woodard, E., Hempelmann, L. H., et al. (1980) · Preventive Medicine · doi:10.1016/0091-7435(80)90024-9 · Cited by 30
Breast cancer in women following mantle irradiation for Hodgkin's disease.
Peters, M. H., Sonpal, I., & Batra, M. K. (1995) · PubMed · Cited by 19
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Lee, C. H., Dershaw, D. D., Kopans, D., Evans, P., Monsees, B., Monticciolo, D., Brenner, R. J., Bassett, L., Berg, W., Feig, S., et al. (2010) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2009.09.022 · Cited by 809
Landier, W., Bhatia, S., Eshelman, D. A., Forte, K. J., Sweeney, T., Hester, A. L., Darling, J., Armstrong, F. D., Blatt, J., Constine, L. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.032 · Cited by 706
Subsequent Neoplasms in 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor Study
Friedman, D. L., Whitton, J., Leisenring, W., Mertens, A. C., Hammond, S., Stovall, M., Donaldson, S. S., Meadows, A. T., Robison, L. L., & Neglia, J. P. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq238 · Cited by 703
Self-citationSecond Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Schaapveld, M., Aleman, B. M. P., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Raemaekers, J. M. M., de Boer, J. P., Zijlstra, J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505949 · Cited by 637
Self-citation
Metadata
- Authors
- Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C. F., Van't Veer, M. B., Glimelius, I., Storm, H., Pukkala, E., Stovall, M., Curtis, R., Boice, J. D., & Gilbert, E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-07-23
- Volume
- 290
- Issue
- 4
- Pages
- 465
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2106193652
- Cited by
- 666
- References
- 37
- FWCI
- 16.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.